Classical Hematology

The investigational drug achieved non-inferiority compared to routine Factor VIII.

These findings build off research from March 2023 that demonstrated efficacy and safety of renizgamglogene autogedtemcel in patients with sickle cell disease.

Mim8 had a safe and well-tolerated profile, with no deaths or thrombotic events reported for patients with hemophilia A.

A 1-time infusion of valoctocogene roxaparvovec had demonstrated sustained bleed control and factor VIII expression in patients with hemophilia A.

Patients with sickle cell disease with more than a 6-month delay transitioning from pediatric to adult care were about twice as likely to be hospitalized.

Antihemophilic factor (recombinant) Fc-VWF-XTEN fusion protein-ehtl was initally approved in February 2023 for adults and children with hemophilia A for prophylaxis and on-demand treatment to control bleeding.

With gene therapy, anti-tissue factor pathway inhibitors, and RNA interference therapy targeting antithrombin, there are many new options that will be available for the patients impacted by hemophilia.

The 1-time treatment may be a better alternative for patients who don’t want to undergo frequent doses of standard of care intravenous factor IX infusions.

The orphan drug designation (ODD) comes after positive results from a phase 2 trial that showed cevidoplenib improved platelet counts by 63.6% and 40.9% in 2 different dose groups.

These disorders can be fatal, making pharmacists’ role in detection crucial.

Most patients with myelofibrosis will develop anemia over the course of the disease, with more than 30% discontinuing treatment as a result.

Corticosteroids are first-line therapy for gaining platelet stability but should only be used short term.

The findings, published the New England Journal of Medicine, showed treatment with rilzabrutinib led to a rapid, durable increase in platelet count while supporting an acceptable safety profile.

Study results showed that an individual with the blood disorder did not respond to treatment, including intravenous immunoglobulin, following their second dose of the Pfizer vaccination.

Experts say the COVID-19 pandemic may create a shortage of plasma therapy.

This activity is supported by educational grants from Dova Pharmaceuticals, INC. and Cure Media Group.